|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
NZ227684A
(en)
|
1988-01-30 |
1991-07-26 |
Merck Sharp & Dohme |
Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
|
|
GB9005737D0
(en)
|
1990-03-14 |
1990-05-09 |
Beecham Group Plc |
Novel compounds
|
|
FR2676444B1
(fr)
*
|
1991-05-16 |
1995-03-10 |
Sanofi Elf |
Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
JP4291143B2
(ja)
|
2001-08-31 |
2009-07-08 |
ジェン−プロウブ インコーポレイテッド |
分析物ポリヌクレオチドを定量するためのアフィニティーシフトしたプローブ
|
|
US7135484B2
(en)
|
2002-08-14 |
2006-11-14 |
Abbott Laboratories |
Azabicyclic compounds are central nervous system active agents
|
|
US7220741B2
(en)
|
2002-09-30 |
2007-05-22 |
Neurosearch A/S |
1,4-diazabicycloalkane derivatives, their preparation and use
|
|
US8014953B2
(en)
|
2003-08-08 |
2011-09-06 |
The Regents Of The University Of California |
RNA surveillance among curated proteins
|
|
US7399765B2
(en)
|
2003-09-19 |
2008-07-15 |
Abbott Laboratories |
Substituted diazabicycloalkane derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309487B2
(en)
|
2004-02-09 |
2007-12-18 |
George Inana |
Methods and compositions for detecting and treating retinal diseases
|
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
CN101223166B
(zh)
|
2004-10-07 |
2011-10-19 |
默沙东公司 |
噻唑基mglur5拮抗剂及其应用方法
|
|
AU2005295441B2
(en)
|
2004-10-18 |
2009-04-23 |
Amgen, Inc. |
Thiadiazole compounds and methods of use
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
CN101146796A
(zh)
|
2005-01-26 |
2008-03-19 |
先灵公司 |
作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
|
|
JP2008536950A
(ja)
|
2005-04-18 |
2008-09-11 |
ニューロジェン・コーポレーション |
置換ヘテロアリールのｃｂ１拮抗薬
|
|
US7598052B2
(en)
|
2005-10-11 |
2009-10-06 |
The Regents Of The University Of Michigan |
Expression profile of thyroid cancer
|
|
US8603457B2
(en)
|
2005-12-02 |
2013-12-10 |
University Of Rochester |
Nonsense suppression and genetic codon alteration by targeted modification
|
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
MX2008014672A
(es)
|
2006-05-19 |
2009-03-09 |
Abbott Lab |
Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
|
|
EP2032575B1
(en)
|
2006-05-30 |
2010-04-07 |
Neurosearch A/S |
Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivative and its medical use
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8343941B2
(en)
|
2007-03-30 |
2013-01-01 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
|
US8283116B1
(en)
|
2007-06-22 |
2012-10-09 |
Ptc Therapeutics, Inc. |
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
|
|
DE102007032507A1
(de)
*
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PL2203173T3
(pl)
|
2007-10-26 |
2016-06-30 |
Academisch Ziekenhuis Leiden |
Środki i sposoby przeciwdziałania zaburzeniom mięśni
|
|
MX2010005648A
(es)
|
2007-11-21 |
2010-06-02 |
Abbott Lab |
Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
|
|
US8437067B2
(en)
|
2008-03-18 |
2013-05-07 |
Konica Minolta Holdings, Inc. |
Electrochemical display element
|
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
MX2011006332A
(es)
|
2008-12-23 |
2011-06-27 |
Abbott Lab |
Compuestos antivirales.
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
CN102625840A
(zh)
|
2009-04-10 |
2012-08-01 |
肌肉学研究协会 |
用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
|
|
KR20200047790A
(ko)
|
2009-06-17 |
2020-05-07 |
바이오젠 엠에이 인코포레이티드 |
대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
|
|
JO3250B1
(ar)
|
2009-09-22 |
2018-09-16 |
Novartis Ag |
إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
|
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
|
US8940762B2
(en)
*
|
2010-01-20 |
2015-01-27 |
Abbvie Inc. |
Methods for treating pain
|
|
BR112012019540B1
(pt)
|
2010-02-05 |
2021-09-28 |
Heptares Therapeutics Limited |
Composto, uso de um composto, formulação farmacêutica, e, processo para a preparação de um composto
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
EP2560488B1
(en)
|
2010-04-23 |
2015-10-28 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
ES2823350T3
(es)
|
2010-07-29 |
2021-05-06 |
Rigel Pharmaceuticals Inc |
Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
|
|
SG193370A1
(en)
|
2011-03-14 |
2013-10-30 |
Nse Products Inc |
Oral formulations for promoting cellular purification
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
WO2013019938A1
(en)
|
2011-08-02 |
2013-02-07 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as eaat2 activators
|
|
WO2013063458A2
(en)
|
2011-10-27 |
2013-05-02 |
Mayo Foundation For Medical Education And Research |
Inhibiting g protein coupled receptor 6 kinase polypeptides
|
|
USRE47689E1
(en)
|
2011-12-30 |
2019-11-05 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
CA2862084C
(en)
|
2012-01-26 |
2021-05-11 |
Ptc Therapeutics, Inc. |
1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
EA037123B1
(ru)
|
2012-02-10 |
2021-02-09 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения спинальной мышечной атрофии
|
|
WO2013130689A1
(en)
|
2012-03-01 |
2013-09-06 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
EP2828247B1
(en)
|
2012-03-23 |
2019-01-16 |
PTC Therapeutics, Inc. |
4h-chromen-4-one derivatives for treating spinal muscular atrophy
|
|
US8729263B2
(en)
*
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
DK2906696T4
(da)
|
2012-10-15 |
2023-02-27 |
Ionis Pharmaceuticals Inc |
Fremgangsmåder til modulering af c9orf72-ekspression
|
|
KR101879920B1
(ko)
*
|
2013-01-15 |
2018-07-18 |
노파르티스 아게 |
알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
|
|
CA2898045C
(en)
*
|
2013-01-15 |
2018-08-28 |
Novartis Ag |
Use of alpha 7 nicotinic acetylcholine receptor agonists
|
|
JP6137336B2
(ja)
*
|
2013-01-15 |
2017-05-31 |
ノバルティス アーゲー |
ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用
|
|
ITMI20130063A1
(it)
*
|
2013-01-17 |
2014-07-18 |
Valier Alberto |
Dispositivo manuale per la raccolta dal suolo di frutti o altri oggetti
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
KR102314290B1
(ko)
|
2013-06-25 |
2021-10-21 |
에프. 호프만-라 로슈 아게 |
척수성 근위축증을 치료하기 위한 화합물
|
|
CN105636953B
(zh)
|
2013-07-31 |
2018-01-02 |
诺华股份有限公司 |
1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
|
|
JP6689197B2
(ja)
|
2013-08-19 |
2020-04-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
スクリーニング方法
|
|
CA2922567A1
(en)
|
2013-08-26 |
2015-03-05 |
Purdue Pharma L.P. |
Azaspiro[4.5]decane derivatives and use thereof
|
|
US9982260B2
(en)
|
2013-09-30 |
2018-05-29 |
The Regents Of The University Of California |
Identification of structurally similar small molecules that enhance therapeutic exon skipping
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
RU2683309C2
(ru)
|
2014-03-14 |
2019-03-28 |
Раквалиа Фарма Инк. |
Азаспиропроизводные в качестве антагонистов trpm8
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
CA2950876A1
(en)
|
2014-06-10 |
2015-12-17 |
Erasmus University Medical Center Rotterdam |
Methods for characterizing alternatively or aberrantly spliced mrna isoforms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
WO2016027168A2
(en)
*
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
WO2016037039A1
(en)
|
2014-09-04 |
2016-03-10 |
Rutgers, The State University Of New Jersey |
Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
|
|
WO2016064895A1
(en)
|
2014-10-20 |
2016-04-28 |
The Brigham And Women's Hospital, Inc. |
Targeting apolipoprotein e (apoe) in neurologic disease
|
|
US10053697B1
(en)
|
2015-01-09 |
2018-08-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Programmable alternative splicing devices and uses thereof
|
|
ES2907461T3
(es)
|
2015-01-20 |
2022-04-25 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
|
|
JP6884102B2
(ja)
|
2015-02-09 |
2021-06-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための化合物
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
EP3310169B1
(en)
*
|
2015-05-30 |
2023-05-17 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
RU2748884C2
(ru)
|
2015-07-20 |
2021-06-01 |
Джензим Корпорейшн |
Ингибиторы рецептора колониестимулирующего фактора-1 (csf-1r)
|
|
US20180271803A1
(en)
|
2015-09-02 |
2018-09-27 |
Pathways Bioscience, Llc |
Compositions and methods for treatment or prevention of oral mucositis
|
|
EP3353167B1
(en)
|
2015-09-24 |
2020-06-24 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
|
WO2017062751A1
(en)
|
2015-10-08 |
2017-04-13 |
The Regents Of The University Of California |
Compounds and methods for promoting stress resistance
|
|
AU2016334804B2
(en)
|
2015-10-09 |
2022-03-31 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
BR112018009281B1
(pt)
|
2015-11-12 |
2023-10-31 |
F. Hoffmann-La Roche Ag |
Composições para tratar atrofia muscular espinhal e seu uso
|
|
WO2017100276A1
(en)
|
2015-12-08 |
2017-06-15 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
|
|
MX382671B
(es)
|
2015-12-10 |
2025-03-13 |
Ptc Therapeutics Inc |
Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
CA3048193A1
(en)
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
|
US10787433B2
(en)
|
2016-01-15 |
2020-09-29 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as EAAT2 activators
|
|
CN115721729A
(zh)
*
|
2016-02-01 |
2023-03-03 |
阿拉基斯医疗公司 |
治疗rna介导的疾病的化合物和方法
|
|
WO2017147312A1
(en)
|
2016-02-23 |
2017-08-31 |
Indiana University Research & Technology Corporation |
Combination therapies for treatment of spinal muscular atrophy
|
|
WO2017147536A1
(en)
|
2016-02-24 |
2017-08-31 |
The Rockefeller University |
Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
|
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
|
US20170268066A1
(en)
|
2016-03-15 |
2017-09-21 |
Chalmers Ventures Ab |
Cancer biomarkers
|
|
EP3436443B1
(en)
|
2016-03-29 |
2020-03-11 |
Merck Patent GmbH |
N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
|
|
AU2017246643B2
(en)
|
2016-04-04 |
2022-08-04 |
University Of Florida Research Foundation, Incorporated |
Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
US10577360B2
(en)
|
2016-04-12 |
2020-03-03 |
Esteve Pharmaceuticals, S.A. |
Arylamide derivatives having multimodal activity against pain
|
|
PT3368069T
(pt)
|
2016-06-13 |
2020-11-11 |
Scholar Rock Inc |
Uso de inibidores da miostatina e terapias de combinação
|
|
SG11201811643TA
(en)
*
|
2016-07-01 |
2019-01-30 |
Arrakis Therapeutics Inc |
Compounds and methods for modulating rna function
|
|
JP2019535789A
(ja)
|
2016-11-28 |
2019-12-12 |
ピーティーシー セラピューティクス，インコーポレーテッド |
Ｒｎａスプライシングを調節する方法
|
|
CN114432318A
(zh)
|
2017-02-20 |
2022-05-06 |
国立大学法人京都大学 |
用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
|
|
US11715549B2
(en)
|
2017-05-01 |
2023-08-01 |
Thomas Jefferson University |
Systems-level analysis of 32 TCGA cancers reveals disease-dependent tRNA fragmentation patterns and very selective associations with messenger RNAs and repeat elements
|
|
CN111372611A
(zh)
*
|
2017-06-14 |
2020-07-03 |
Ptc医疗公司 |
修饰rna剪接的方法
|
|
MX2019015580A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
MX2019015578A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
MY201938A
(en)
|
2017-08-04 |
2024-03-25 |
Skyhawk Therapeutics Inc |
Methods and compositions for modulating splicing
|
|
EP3686196B1
(en)
|
2017-09-20 |
2024-06-12 |
Hangzhou Innogate Pharma Co., Ltd. |
Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
|
|
AU2018347516A1
(en)
|
2017-10-12 |
2020-05-07 |
Revolution Medicines, Inc. |
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
|
|
US20190167815A1
(en)
|
2017-10-24 |
2019-06-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of rare diseases
|
|
EP3479845A1
(en)
|
2017-11-06 |
2019-05-08 |
Stalicla S.A. |
Challenge test for diagnosing subtype of autism spectrum disease
|
|
US10905707B2
(en)
|
2017-11-10 |
2021-02-02 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
CN112272666A
(zh)
|
2018-04-10 |
2021-01-26 |
斯基霍克疗法公司 |
用于治疗癌症的化合物
|
|
WO2020004594A1
(ja)
|
2018-06-27 |
2020-01-02 |
株式会社リボルナバイオサイエンス |
脊髄性筋萎縮症の予防または治療剤
|
|
EA202092899A1
(ru)
|
2018-06-27 |
2021-05-14 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Гетероарильные соединения для лечения болезни гентингтона
|
|
US11685746B2
(en)
|
2018-06-27 |
2023-06-27 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating Huntington's disease
|
|
LT3814357T
(lt)
|
2018-06-27 |
2024-06-25 |
Ptc Therapeutics, Inc. |
Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
|
|
WO2020028814A1
(en)
|
2018-08-03 |
2020-02-06 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Allosteric inhibitor of wee1 kinase
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
US11129829B2
(en)
*
|
2019-06-17 |
2021-09-28 |
Skyhawk Therapeutics, Inc. |
Methods for modulating splicing
|
|
JP2023515617A
(ja)
|
2020-02-28 |
2023-04-13 |
リミックス セラピューティクス インコーポレイテッド |
核酸スプライシングを調節するためのピリダジン誘導体
|
|
MX2022010683A
(es)
|
2020-02-28 |
2023-01-19 |
Remix Therapeutics Inc |
Compuestos y metodos para modular el empalme.
|
|
JP2023515619A
(ja)
|
2020-02-28 |
2023-04-13 |
リミックス セラピューティクス インコーポレイテッド |
スプライシングを調節するための化合物及び方法
|
|
CA3169697A1
(en)
|
2020-02-28 |
2021-09-02 |
Dominic Reynolds |
Thiophenyl derivatives useful for modulating nucleic acid splicing
|
|
EP4132646A1
(en)
|
2020-04-08 |
2023-02-15 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
WO2021207550A1
(en)
|
2020-04-08 |
2021-10-14 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|